Citigroup
IMVT icon

Citigroup’s Immunovant IMVT Stock Holding History

Citigroup’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.82M Buy
+54,000
New +$2.13M ﹤0.01% 2887
2025
Q2 		– Sell
-59,200
Closed -$1.01M – 5771
2025
Q1 		$1.01M Hold
59,200
– – ﹤0.01% 3256
2024
Q4 		$1.47M Buy
59,200
+29,700
+101% +$842K ﹤0.01% 3062
2024
Q3 		$841K Buy
+29,500
New +$870K ﹤0.01% 3394
2023
Q2 		– Sell
-38,900
Closed -$603K – 5638
2023
Q1 		$603K Buy
+38,900
New +$675K ﹤0.01% 2982

Other funds holding IMVT

Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Banque Pictet & Cie
Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return
Alchemi Wealth
Alchemi Wealth Essex, Connecticut $223M AUM 31.82% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Citigroup's IMVT Position: Q3 2026 in Review

Citigroup reduced its Immunovant (IMVT) stake by 58% in Q3 2026, selling an estimated $2.64M and leaving 49,254 shares worth $1.66M. The position accounts for ﹤0.01% of the portfolio, ranked #2959.

Citigroup first reported a position in IMVT in Q1 2020 and has held it in 27 quarters since. The position peaked at $8.07M in Q1 2024. 53 funds tracked by Wall St. Rank hold IMVT as of Q3 2026.

  • Citigroup held 49,254 shares of Immunovant worth $1.66M as of Q3 2026.
  • Citigroup sold 66,891 Immunovant shares in Q3 2026, an estimated $2.64M.
  • Immunovant made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #2959 holding.
  • Citigroup first reported a position in Immunovant in Q1 2020 and has held it in 27 quarters since.
  • Citigroup's Immunovant position peaked at $8.07M in Q1 2024.
  • 53 funds tracked by Wall St. Rank held Immunovant as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.